Selected trials that include patients with Ph− MPN-AP or MPN-BP
| Agent . | Mechanism of action . | Trial phase . | Disease . | Clinicaltrials.gov ID . |
|---|---|---|---|---|
| Ruxolitinib + decitabine | JAK inhibition + HMA | 1/2 | MPN-AP/MPN-BP | NCT02076191 |
| Ruxolitinib + decitabine | JAK inhibition + HMA | 1/2 | MPN-AP/MPN-BP | NCT02257138 |
| SGI-110 | HMA | 2 | Ph− MPN, including MF-AP | NCT03075826 |
| Various | Various molecularly targeted | 1/2 | AML-TN in older adults; includes MPN-BP | NCT03013998 |
| Enasidenib or ivosidenib + azacitdine | IDH2 or IDH1 inhibition + HMA | 1/2 | AML-TN; includes MPN-BP | NCT02677922 |
| Azacitidine ± ivosidenib | HMA ± IDH1 inhibition | 3 | AML-TN; includes MPN-BP; not candidate for IC | NCT03173248 |
| Ivosidenib or enasidenib + cytarabine/daunorubicin | IDH1 or IDH2 inhibition + IC | 1 | AML-TN; includes MPN-BP | NCT02632708 |
| Venetoclax + ivosidenib | BCL2 inhibition + IDH1 inhibition | 1 | Advanced heme malignancies, including MPN-AP/MPN-BP | NCT03471260 |
| Decitabine | HMA | 2 | TP53-mutated R/R AML | NCT03063203 |
| Decitabine + pevonedistat | HMA + NAE inhibition | 1 | R/R AML, including secondary AML; AML-TN, age >60 y; not candidate for IC | NCT03009240 |
| Azacitidine + selumetinib | HMA + MEK inhibition | 1 | Advanced myeloid neoplasms, including MPN-AP | NCT03326310 |
| XmAb14045 | CD123 BiTE antibody | 1 | Advanced CD123+ heme malignancies, including R/R AML | NCT0273012 |
| Agent . | Mechanism of action . | Trial phase . | Disease . | Clinicaltrials.gov ID . |
|---|---|---|---|---|
| Ruxolitinib + decitabine | JAK inhibition + HMA | 1/2 | MPN-AP/MPN-BP | NCT02076191 |
| Ruxolitinib + decitabine | JAK inhibition + HMA | 1/2 | MPN-AP/MPN-BP | NCT02257138 |
| SGI-110 | HMA | 2 | Ph− MPN, including MF-AP | NCT03075826 |
| Various | Various molecularly targeted | 1/2 | AML-TN in older adults; includes MPN-BP | NCT03013998 |
| Enasidenib or ivosidenib + azacitdine | IDH2 or IDH1 inhibition + HMA | 1/2 | AML-TN; includes MPN-BP | NCT02677922 |
| Azacitidine ± ivosidenib | HMA ± IDH1 inhibition | 3 | AML-TN; includes MPN-BP; not candidate for IC | NCT03173248 |
| Ivosidenib or enasidenib + cytarabine/daunorubicin | IDH1 or IDH2 inhibition + IC | 1 | AML-TN; includes MPN-BP | NCT02632708 |
| Venetoclax + ivosidenib | BCL2 inhibition + IDH1 inhibition | 1 | Advanced heme malignancies, including MPN-AP/MPN-BP | NCT03471260 |
| Decitabine | HMA | 2 | TP53-mutated R/R AML | NCT03063203 |
| Decitabine + pevonedistat | HMA + NAE inhibition | 1 | R/R AML, including secondary AML; AML-TN, age >60 y; not candidate for IC | NCT03009240 |
| Azacitidine + selumetinib | HMA + MEK inhibition | 1 | Advanced myeloid neoplasms, including MPN-AP | NCT03326310 |
| XmAb14045 | CD123 BiTE antibody | 1 | Advanced CD123+ heme malignancies, including R/R AML | NCT0273012 |
BiTE, bispecific T cell engaging; NAE, Nedd8-activating enzyme inhibitor; TN, treatement naïve.